Alnylam Pharmaceuticals (NASDAQ:ALNY) Research Coverage Started at StockNews.com

Equities researchers at StockNews.com initiated coverage on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Rating) in a research report issued on Thursday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

A number of other research analysts have also issued reports on the company. Morgan Stanley reduced their price target on Alnylam Pharmaceuticals from $210.00 to $205.00 and set an “equal weight” rating for the company in a research report on Friday, February 24th. Canaccord Genuity Group reduced their price target on Alnylam Pharmaceuticals from $310.00 to $291.00 and set a “buy” rating for the company in a research report on Friday, February 24th. Chardan Capital reiterated a “buy” rating and set a $250.00 price target on shares of Alnylam Pharmaceuticals in a research report on Friday, February 24th. Citigroup cut their price objective on Alnylam Pharmaceuticals from $270.00 to $265.00 and set a “buy” rating for the company in a report on Friday, February 24th. Finally, SVB Leerink cut their price objective on Alnylam Pharmaceuticals from $144.00 to $143.00 and set a “market perform” rating for the company in a report on Monday, January 23rd. Seven equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $244.26.

Alnylam Pharmaceuticals Price Performance

Shares of ALNY opened at $185.75 on Thursday. The company has a market cap of $23.06 billion, a P/E ratio of -19.99 and a beta of 0.49. The stock has a fifty day moving average price of $215.55 and a 200 day moving average price of $213.71. The company has a debt-to-equity ratio of 3.85, a current ratio of 3.51 and a quick ratio of 3.34. Alnylam Pharmaceuticals has a 12 month low of $117.58 and a 12 month high of $242.97.

Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Rating) last issued its quarterly earnings data on Thursday, February 23rd. The biopharmaceutical company reported ($1.68) EPS for the quarter, topping analysts’ consensus estimates of ($2.13) by $0.45. Alnylam Pharmaceuticals had a negative return on equity of 1,287.80% and a negative net margin of 109.04%. The firm had revenue of $335.04 million during the quarter, compared to the consensus estimate of $312.45 million. During the same period in the prior year, the business earned ($2.16) EPS. The firm’s revenue was up 29.6% on a year-over-year basis. On average, research analysts forecast that Alnylam Pharmaceuticals will post -6.85 earnings per share for the current year.

Insider Activity at Alnylam Pharmaceuticals

In related news, CMO Pushkal Garg sold 18,072 shares of the company’s stock in a transaction on Friday, March 3rd. The stock was sold at an average price of $200.00, for a total transaction of $3,614,400.00. Following the transaction, the chief marketing officer now directly owns 4,345 shares of the company’s stock, valued at $869,000. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, CMO Pushkal Garg sold 18,072 shares of the company’s stock in a transaction on Friday, March 3rd. The stock was sold at an average price of $200.00, for a total transaction of $3,614,400.00. Following the transaction, the chief marketing officer now directly owns 4,345 shares of the company’s stock, valued at $869,000. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Indrani Lall Franchini sold 1,675 shares of the company’s stock in a transaction on Thursday, February 2nd. The shares were sold at an average price of $226.01, for a total value of $378,566.75. Following the transaction, the executive vice president now directly owns 3,500 shares in the company, valued at $791,035. The disclosure for this sale can be found here. 1.40% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Belpointe Asset Management LLC acquired a new position in Alnylam Pharmaceuticals in the 4th quarter worth about $25,000. ANTIPODES PARTNERS Ltd acquired a new position in Alnylam Pharmaceuticals in the 4th quarter worth about $28,000. Guardian Wealth Advisors LLC acquired a new position in Alnylam Pharmaceuticals in the 3rd quarter worth about $27,000. Allworth Financial LP increased its position in Alnylam Pharmaceuticals by 708.7% in the 3rd quarter. Allworth Financial LP now owns 186 shares of the biopharmaceutical company’s stock worth $37,000 after purchasing an additional 163 shares during the last quarter. Finally, SeaCrest Wealth Management LLC acquired a new position in Alnylam Pharmaceuticals in the 2nd quarter worth about $44,000.

About Alnylam Pharmaceuticals

(Get Rating)

Alnylam Pharmaceuticals, Inc is a global commercial-stage biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. Its products include ONPATTRO, GIVLAARI, and OXLUMO. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R.